Randomized, double‐blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease
- 1 October 2003
- journal article
- clinical trial
- Published by Wiley in Movement Disorders
- Vol. 18 (10) , 1149-1156
- https://doi.org/10.1002/mds.10508
Abstract
We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment. © 2003 Movement Disorder SocietyKeywords
This publication has 13 references indexed in Scilit:
- Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre studyJournal of Neurology, Neurosurgery & Psychiatry, 1999
- Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's diseaseNeurology, 1997
- Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's diseaseNeurology, 1997
- Safety and Efficacy of Pramipexole in Early Parkinson DiseaseJAMA, 1997
- Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuationsNeurology, 1996
- The levodopa dose-sparing capacity of pergolide compared with that of bromocriptine in an open-label, crossover studyEuropean Journal of Neurology, 1996
- Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptorsEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled studyMovement Disorders, 1994
- Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonistEuropean Journal of Pharmacology, 1992
- Comparison of pergolide and bromocriptine therapy in parkinsonismNeurology, 1983